Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Adzynma Generic Name & Formulations
Legal Class
General Description
How Supplied
Single-dose vial—1 (w. supplies)
Manufacturer
Generic Availability
NO
Mechanism of Action
Adzynma is a recombinant form of the endogenous ADAMTS13. ADAMTS13 is a plasma zinc metalloprotease that regulates the activity of von Willebrand factor (VWF) by cleaving large and ultralarge VWF multimers to smaller units and thereby reducing the platelet binding properties of VWF and its propensity to form microthrombi.
Adzynma Indications
Indications
For prophylactic or on demand enzyme replacement therapy (ERT) in patients with congenital thrombotic thrombocytopenic purpura (cTTP).
Adzynma Dosage and Administration
Adults and Children
Give as IV infusion at a rate of 2–4mL/min. Prophylaxis: 40 IU/kg once every other week; may give once weekly based on prior prophlylactic regimen or clinical response. On-demand: 40 IU/kg on Day 1, then 20 IU/kg on Day 2, then 15 IU/kg once daily from Day 3 and beyond until 2 days after acute event resolved.
Adzynma Contraindications
Not Applicable
Adzynma Boxed Warnings
Not Applicable
Adzynma Warnings/Precautions
Warnings/Precautions
Immediately discontinue if severe allergic reactions occur. Potential for immunogenicity. Neutralizing antibodies may develop. Pregnancy. Nursing mothers.
Adzynma Pharmacokinetics
See Literature
Adzynma Interactions
Not Applicable
Adzynma Adverse Reactions
Adverse Reactions
Headache, diarrhea, migraine, abdominal pain, nausea, upper RTI, dizziness, vomiting; hypersensitivity reactions.
Adzynma Clinical Trials
See Literature
Adzynma Note
Not Applicable
Adzynma Patient Counseling
See Literature
Images
